Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 1999

View Archived Issues

Small-molecule thrombopoietic compounds in development at Kyowa Hakko

Merck & Co.: Annual Report 1998

Pharmacokinetic evaluation of CDK inhibitor indicates need for short dosing interval

Multiple mechanisms of cytotoxic activity described for FR-901228

Genentech's NGF disappointing in phase III trial

Novel Roche peptides useful for bone disorders

IP receptor antagonists from Roche with potential as analgesic/antiinflammatory agents

FDA approves Fragmin for DVT after hip replacement surgery

Xenova presents novel topoisomerase inhibitor at AACR

Broad-spectrum antifungal agents in development at Merck

Warner-Lambert prepares naphthyridinone kinase and cell proliferation inhibitors

News from AACR: DNA topoisomerases as a preferred target for new anticancer drugs

Abbott's A-105972: new antimitotic agent presented at AACR meeting

News from AACR meeting: NCI evaluating new aminoflavone in preclinical studies

U.S. patent issued to Procyon for scar prevention therapy

Second-generation RAMBA selected by Janssen as development candidate

Pierre Fabre features topoisomerase inhibitor in several AACR presentations

Onyvax awarded grant for cancer vaccines

SR-271425: new thioxanthone with promising preclinical antitumor activity

Eye implant receives FDA approval for correcting mild myopia

Antitumor activity of intratumoral DTI-015 assessed in two rat models

Celebrex approved as arthritis treatment in Switzerland

Mitsui develops MS-247, a novel DNA minor groove-binding agent

D-24851 --a new tubulin-interacting agent with oral activity and improved therapeutic index

Chemical modification of magainin peptide results in effective, nontoxic antitumor compound

Karenitecin compound BNP-1350, a promising candidate for treating pediatric cancers

Synvisc approved, launched in South Africa

Parke-Davis team achieves excellent preclinical results with new EGF receptor TK inhibitor

TX-1123: a lead PK-inhibitory antitumor agent without mitochondrial toxicity

Preliminary analysis of Biomira's synthetic cancer vaccine